Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept c...

Celý popis

Podrobná bibliografia

Vydané v:	EBioMedicine Ročník 66; s. 103310
Hlavní autori:	Talaat, Kawsar R., Alaimo, Cristina, Martin, Patricia, Bourgeois, A. Louis, Dreyer, Anita M., Kaminski, Robert W., Porter, Chad K., Chakraborty, Subhra, Clarkson, Kristen A., Brubaker, Jessica, Elwood, Daniel, Frölich, Rahel, DeNearing, Barbara, Weerts, Hailey, Feijoo, Brittany L., Halpern, Jane, Sack, David, Riddle, Mark S., Fonck, Veronica Gambillara
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.04.2021 Elsevier
Predmet:	Advanced Basic Science Bioconjugate vaccine Controlled human challenge study Internal Medicine Research Paper Shigella Shigella flexneri 2a Vaccine Controlled human challenge study Vaccine Shigella flexneri 2a Bioconjugate vaccine Shigella
ISSN:	2352-3964, 2352-3964
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!